1 Aug 2018 16:47
Amphion Innovations plc
("Amphion" or "the Company")
Results of AGM
London and New York, 1 August 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, today announces that all resolutions were passed at the Annual General Meeting, which was held on Wednesday 1 August 2018.
For further information please contact:
Amphion Innovations | Tel: +1 (212) 210 6224 | |||||
Charlie Morgan | ||||||
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate Broker) | Tel: +44 (0)20 7886 2500 | |||||
Freddy Crossley / Emma Earl / Ryan McCarthy (Corporate Finance) | ||||||
Charlie Leigh-Pemberton (Corporate Broking) | ||||||
Northland Capital Partners Limited (Joint Corporate Broker) | Tel: +44 (0)20 3861 6625 | |||||
David Hignell (Corporate Finance) | ||||||
Vadim Alexandre (Corporate Broking) | ||||||
Walbrook PR | Tel: +44 (0)20 7933 8780 or | |||||
Paul McManus/ Anna Dunphy | amphion@walbrookpr.com | |||||
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.
We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.
On the web: www.amphionplc.com